Abstract | BACKGROUND: METHODS: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial is a multicenter, randomized, double-blind, active-controlled, 24-week trial in 25,302 patients with untreated or uncontrolled hypertension conducted in 3298 office-based sites in 12 countries. Subjects were randomized to omapatrilat 10 mg or enalapril 5 mg as initial therapy for hypertension (group 1, n = 9292), replacement for existing antihypertensive therapy (group 2, n =11,224), or in addition to existing antihypertensive therapy (group 3, n = 4751). Study drug was force-titrated at week 2 and electively titrated at weeks 4 and 6 to a maximum of omapatrilat 80 mg or enalapril 40 mg once daily. At weeks 8 and 16, adjunctive antihypertensive medications were added electively to achieve target BP. RESULTS: CONCLUSIONS:
|
Authors | John B Kostis, Milton Packer, Henry R Black, Roland Schmieder, David Henry, Elliott Levy |
Journal | American journal of hypertension
(Am J Hypertens)
Vol. 17
Issue 2
Pg. 103-11
(Feb 2004)
ISSN: 0895-7061 [Print] United States |
PMID | 14751650
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Pyridines
- Thiazepines
- omapatrilat
- Enalapril
- Metalloendopeptidases
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Angioedema
(chemically induced)
- Antihypertensive Agents
(adverse effects, therapeutic use)
- Double-Blind Method
- Enalapril
(adverse effects, therapeutic use)
- Female
- Humans
- Hypertension
(drug therapy)
- Male
- Metalloendopeptidases
(antagonists & inhibitors)
- Middle Aged
- Pyridines
(adverse effects, therapeutic use)
- Thiazepines
(adverse effects, therapeutic use)
- Treatment Outcome
|